CAR-T cell therapy for colorectal cancer in the liver
Part of Cancer, Digestive system clinical trials.
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18–75 years old (any sex).
- You had surgery to remove the main colorectal tumor and liver metastases with clean margins (no visible remaining tumor).
- Your cancer tissue shows high CEA protein (stain shows more than 50%) in both the original tumor and liver spot.
- Tests after chemo show “MRD” is still positive or comes back (a sign of tiny cancer cells that can’t be seen).
- Your health is strong enough for treatment: good heart/lung function, good kidney and liver blood tests, and you can do daily activities (performance score 0–2).
- You can provide enough blood cells for manufacturing the CAR-T treatment, and you will use effective contraception if you can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
This trial tests a special immune cell therapy (CAR-T) that targets a protein called CEA on cancer cells. It is for people with colorectal cancer that has spread to the lining of the belly (peritoneum) and who have already had surgery to remove as much of the spread as possible.
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.